Background: General anesthetics can modulate the 5-hydroxytryptamine type 3 (5-HT 3 ) receptor, which may be involved in processes mediating nausea and vomiting, and peripheral nociception. The effects of the new volatile anesthetic sevoflurane and the gaseous anesthetics nitrous oxide (N 2 O) and xenon (Xe) on the 5-HT 3 receptor have not been well-characterized.
THE 5-hydroxytryptamine type 3 (5-HT 3 ) receptor is a member of the superfamily of ligand-gated ion channel receptors sharing structural similarities with the nicotinic acetylcholine, glycine, and ␥-aminobutyric acid type A (GABA A ) receptors. 1 Most receptors of this superfamily are modulated by general anesthetics. 2 The 5-HT 3 receptors are diffusely distributed in both the central and peripheral nervous system and are involved in physiologic and pathologic processes mediating nausea and vomiting, peripheral nociception, and central antinociception. 3 Volatile and intravenous anesthetics and alcohol can variously modulate 5-HT 3 receptor function. 4 -7 Volatile anesthetics and alcohol potentiate 5-HT 3 receptor function, 4, 5 whereas intravenous anesthetics, such as pentbarbital 6 and propofol, 7 inhibit 5-HT 3 receptor function. Because one of the physiologic effects of anesthetics is modulation of the 5-HT 3 receptor, the enhancement of 5-HT 3 receptor responses by volatile anesthetics has been suggested as the underlying mechanism of postoperative nausea and vomiting (PONV). 8 Taken together with the fact that specific 5-HT 3 receptor antagonists, such as ondansetron, may alleviate PONV, 9 -11 the potentiation of the 5-HT 3 receptor by volatile anesthetics might be associated with the mechanism of PONV. However, the effects on the 5-HT 3 receptor of gaseous anesthetics, such as nitrous oxide (N 2 O), which is widely used in clinical practice, and xenon (Xe), which has recently been focused on for clinical use, have not been well-characterized. 12 In this study, we used electrophysiologic techniques to examine and compare the effects of three volatile anesthetics (halothane, isoflurane, and sevoflurane) and two gaseous anesthetics (N 2 O and Xe) on cloned human 5-HT 3A receptors expressed in Xenopus oocytes.
Materials and Methods

Expression of Human 5-HT 3A Receptor in Xenopus Oocytes
Human-cloned 5-HT 3A complementary DNA (cDNA) was kindly provided by Akira Miyake, Ph.D. (Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Ibaragi, Japan). 13 The cDNA encoding the human 5-HT 3A receptor was subcloned into pBluescriptII (Stratagene, La Jolla, CA) and was linearized by EcoR1 (Wako Pure Chemical Industries, Ltd., Osaka, Japan) to create the template cDNA. Capped complementary RNA (cRNA) was synthesized in vitro from cDNA using T 3 RNA polymerase (T3 mMESSAGE mMACHINE KIT; Ambion, Austin, TX) according to the manufacturer's instructions. In accordance with the study protocol approved by the Animal Research Committee of Osaka University Medical School (Osaka, Japan), female Xenopus laevis were anesthetized on ice with 1% 3-aminobenzoic ethyl ester (Tricaine; Sigma, St. Louis, MO). Oocytes were harvested through a laparotomy incision, manually defolliculated with forceps, and treated with 1.5 mg/ml collagenase type 1A (Sigma) for 30 min at room temperature in modified Barth saline (MBS: 88 mM NaCl, 1 mM KCl, 10 mM HEPES, 1 mM MgCl 2 , 2.4 mM NaHCO 3 ; pH 7.4). Between 10 and 50 ng cRNA was injected into an oocyte with a glass capillary, using a Nanoject injector (Drummond Scientific, Broomall, PA). Oocytes were incubated at 20°C in MBS containing 1.8 mM Ca 2ϩ until the start of the electrophysiologic experiment.
Electrophysiology
Between 24 and 48 h after cRNA injection, the oocytes were placed in a 0.2-ml chamber and were continuously superfused with MBS containing 1.8 mM CaCl 2 at 5-10 ml/min. The electrophysiologic recordings were made using a two-electrode, voltage clamp technique. The oocytes were impaled with 1-to 5-M⍀ electrodes filled with 3 M KCl solution and were voltage clamped at Ϫ70 mV (CEZ-1250; Nihon Kohden, Tokyo, Japan). Drugs were dissolved in MBS and applied to the perfusate. Volatile and gaseous anesthetics were added to the perfusate by bubbling anesthetic-containing gases with or without 5-hydroxytryptamine (5-HT). A 50-ml conical tube (Corning 430291; Corning, NY) was filled with solution, and anesthetic gases were continuously bubbled into the tube at a rate of 100 ml/min. For volatile anesthetics (halothane, isoflurane, and sevoflurane), the air was passed through the following calibrated vaporizers: Fluotec3 for halothane (Ohmeda, Steeton, West Yorkshire, United Kingdom), Forawick for isoflurane (Murako Medical, Tokyo, Japan) and Sevotec3 for sevoflurane (Ohmeda). For gaseous anesthetics (N 2 O and Xe), gas mixtures at different concentrations of each gas were prepared using precise flowmeters (PMG-1; KOFLOC Co., Ltd., Kyoto, Japan). The concentrations of N 2 O and Xe in the gas mixtures were measured using a Datex Capnomac Ultima (Datex Instrumentarium Corp., Helsinki, Finland) and a Xe meter (Riken, Tokyo, Japan), respectively. The concentration of oxygen or nitrogen in the control solution was adjusted to the same level as the oxygen concentration in the anesthetic solution. Anesthetic solutions were bubbled with the anesthetic-containing gas mixture for 30 min. Anesthetic solutions were preapplied to oocytes before exposure to 5-HT to allow time for equilibrium. Each drug application was separated by intervals of a few minutes and by longer intervals after application of high drug concentrations to eliminate receptor desensitization. Cumulative desensitization was excluded by confirming that the same response was induced by a low concentration of 5-HT during an experiment with one oocyte. The current was digitally recorded using AxoScope software (Axon Instruments, Burlingame, CA), running on an IBM personal computer (IBM Aptiva, Armonk, NY). All electrophysiologic experiments were performed at room temperature.
Determination of Anesthetic Concentration in Solutions
The different concentrations of volatile and gaseous anesthetics in solution were determined by gas chromatography-mass spectrometry-selected ion monitoring (GC-MS-SIM). 14, 15 A gas chromatograph (Trace GC2000, ThermoQuest; CE Instruments, Austin, TX) and mass spectrometer (GCQ plus, ThermoQuest; CE Instruments) equipped with a data processing system (Xcaliber, ThermoQuest; CE Instruments) were used. The capillary column used was DB-5MS (0.25 mm ID ϫ 30 m; J&W Scientific, Folsom, CA). Using the head space sampling technique, 14 the concentrations of anesthetic in the solution and gas phase were measured using an automatic gas sampler (COMBI PAL; CTC Analytics AG, Zwingen, Switzerland). The ion intensities of isoflurane, sevoflurane, N 2 O, and Xe were monitored using mass/ charge values (m/z) of 51, 51, 30, and 129, respectively. The anesthetic peak spectra areas were measured and compared to determine the gas/MBS partition. The gas/ solution partition coefficient (P) of each anesthetic at 25°C was calculated using the following equation: P ϭ C Ring /C gas , where C gas and C Ring are the equilibrated concentrations of anesthetic in the gas phase and MBS. Then the actual concentration of each anesthetic in the experimental solution was determined by using the absolute calibration curve established for each anesthetic in solution.
Data Analysis
Peak amplitudes of the current elicited by the drugs were measured directly from digital recordings stored in AxoScope. To obtain the concentration-response curve for 5-HT-induced currents, observed peak amplitudes were normalized and plotted and then fitted to the Hill equation below using Sigmaplot software (Jandel Scientific, San Rafael, CA):
where I is the peak current at a given concentration of 5-HT, I max is the maximum current, EC 50 is the concentration of 5-HT eliciting a half-maximum response, and n denotes the Hill coefficient. Statistical analyses were performed using the Student t test, with significance levels set at P Ͻ 0.05. All data were expressed as mean Ϯ standard error of the mean. The anesthetics were sourced as follows: halothane (Takeda Chemical Industries, Osaka, Japan), isoflurane (Abbott Laboratories Ltd., Chicago, IL), sevoflurane (Maruichi Pharmaceutical Co., Ltd., Osaka, Japan), N 2 O (Teisan Ltd., Tokyo, Japan), and Xe (99.995%; AirWater Co. Ltd., Wakayama, Japan).
Results
The gas/MBS partition coefficient of each anesthetic at 25°C was calculated based on measurements made using GC-MS-SIM, and was 1.12 Ϯ 0.02 for halothane, 1.04 Ϯ 0.01 for isoflurane, 0.63 Ϯ 0.01 for sevoflurane, 0.94 Ϯ 0.03 for N 2 O, and 0.12 Ϯ 0.01 for Xe. The actual concentrations of the anesthetics in the MBS used in this study are summarized in table 1.
We confirmed that the 5-HT-induced currents in oocytes injected with human 5-HT 3A receptor cRNA were reversibly blocked by the selective 5-HT 3 receptor antagonist ramosetron (data not shown). The peaks of the 5-HT-induced currents were concentration dependent, and the 5-HT concentration-response curve fitted well to the Hill equation, with an EC 50 of 2.7 Ϯ 0.1 M and a Hill coefficient of 1.7 Ϯ 0.1.
Applications of all volatile (up to 4%) and gaseous (up to 100%) anesthetics without 5-HT produced no detectable current (data not shown). To exclude the involvement of oxygen and nitrogen concentrations in the 5-HT-induced current, we evaluated the effects of the perfusates, which contain 5-HT under various concentrations of these gases (0 -100%). The control currents induced by 5-HT were not affected by the concentration of oxygen or nitrogen in the perfusate (data not shown). Figure 1 shows the traces of 5-HT-induced currents potentiated and inhibited by the anesthetics. The potentiation and inhibition by the anesthetics were fully reversible. The volatile anesthetics halothane and isoflurane potentiated the 5-HT-induced current at clinical concentrations. The currents induced by 1 M 5-HT, which was equivalent to EC 15 , were enhanced by 0.5, 1, 2, and 4% halothane to 154 Ϯ 9, 182 Ϯ 12, 196 Ϯ 15, and 263 Ϯ 14%, and by 0.5, 1, 2, and 4% isoflurane to 110 Ϯ 2, 117 Ϯ 2, 132 Ϯ 4, and 151 Ϯ 8%, respectively. Halothane potentiated the 5-HT-induced current to a larger degree than did isoflurane at the same concentration. In contrast, the volatile anesthetic sevoflurane and the gaseous anesthetics N 2 O and Xe inhibited 5-HTinduced currents. Sevoflurane reduced 1 M 5-HT-induced currents to 89 Ϯ 2, 76 Ϯ 1, 56 Ϯ 3, and 33 Ϯ 2% at concentrations of 0.5, 1, 2, and 4%, respectively. N 2 O inhibited the current to 88 Ϯ 1, 77 Ϯ 4, and 64 Ϯ 3%, and Xe inhibited the current to 51 Ϯ 3, 34 Ϯ 4, and 21 Ϯ 4% at concentrations of 35, 70, and 100%, respectively. Xe inhibited the current more potently than did N 2 O over the range of concentrations tested. These potentiating and inhibitory effects by anesthetics on 5-HT-induced currents were all concentration dependent ( fig. 2 ). The concentration-response curves of 5-HT were obtained in the absence and presence of 1% sevoflurane, 100% N 2 O, and 100% Xe, respectively ( fig. 3 ). Sevoflurane reduced the maximal response without changing the EC 50 values (2.7 Ϯ 0.1 and 2.8 Ϯ 0.2 M, respectively), but N 2 O and Xe shifted the concentration-response curves of 5-HT to the right without changing the maximal responses. The EC 50 value of 5-HT was shifted to 4.0 Ϯ 0.4 M for N 2 O and to 4.1 Ϯ 0.2 M for Xe. These data indicate that these anesthetics inhibit the 5-HT 3 receptor according to different mechanisms, with sevoflurane acting noncompetitively and N 2 O and Xe acting competitively. The inhibitory effects of these three anesthetics were also examined at various membrane potentials. The effects of 2% sevoflurane, 70% N 2 O, and 70% Xe were not significantly different for membrane potentials ranging from Ϫ90 mV to ϩ30 mV (Student t test, P Ͼ 0.05) ( fig. 4 ).
Discussion
The 5-HT 3 receptor belongs to the superfamily of ligand-gated ion channels, which includes the nicotinic acetylcholine (nACh), glycine, and GABA A receptors. 1 Two 5-HT 3 receptor subunits, 5-HT 3A 16 and 5-HT 3B , 17 have been identified. The 5-HT 3A subunit has been cloned from various species (mouse, rat, human) and can exist as a homomeric receptor in some systems (e.g., mouse neuroblastoma N1E-115 and dorsal root ganglion neurons). The heteromeric receptor, comprising 5-HT 3A and 5-HT 3B subunits, can exist in some regions of the brain and displays distinctive pharmacologic properties, especially with an antagonist such as tubocurarine. 17 Although there is no information available about the pharmacologic difference between the effect of anesthetics on homomeric and heteromeric 5-HT 3 receptors, research into anesthetic effects in the heteromeric 5-HT 3 receptor may be necessary to provide a better understanding of the clinical significance of the effect of anesthetics on the 5-HT 3 receptor. Miyake et al. reported interspecies differences not only in terms of structure but also in terms of tissue distribution and pharmacologic profile. 13 The affinity of the human 5-HT 3 receptor for the 5-HT 3 receptor agonist m-chlorophenylbiguanide was much lower than that seen in the rat 5-HT 3 receptor, and 2-methyl-5-HT, a partial agonist for the mouse 5-HT 3 receptor, was a full agonist for the human 5-HT 3 receptor. 13 In native neurons, the dissociative anesthetic ketamine potentiated 5-HT 3 receptor function in a rabbit nodose ganglion neuron at clinical concentrations. 18 Ketamine at similar concentrations failed to modulate recombinant murine 5-HT 3 receptor expressed in oocytes, whereas high concentrations produced inhibition of function. 19 Therefore, the pharmacologic responses of the 5-HT 3 receptors to anesthetics seem to differ among species. Our data showed 1% (0.41 mM) halothane and 1% (0.48 mM) isoflurane potentiated 1 M (EC 15 ) 5-HT-induced currents of a human recombinant 5-HT 3 receptor to 181.9 and 116.9%, respectively. These results were consistent with those of previous reports. Machu et al. 5 reported 0.75 M 5-HT-induced currents of a NCB-20 recombinant 5-HT 3 receptor were potentiated by 0.15 mM halothane and isoflurane to 133 and 111%, respectively. Jenkins et al. 4 reported that in N1E-115 neuroblastoma cells, 0.21 mM halothane, and 0.31 mM isoflurane potentiated 1 M 5-HT-induced currents to almost 150 and 115%. The larger potentiations with halothane than with isoflurane at clinically relevant concentrations were found in 5-HT 3 receptors from various species. Anesthetic action on the 5-HT 3A receptor seems to show no difference between species.
The 5-HT 3 receptor has received considerable attention recently in relation to general anesthetics. 20 Most volatile anesthetics, such as halothane, isoflurane, enflurane, and methoxyflurane, at clinical concentrations potentiated 5-HT-induced currents in 5-HT 3 receptors in N1E-115 neuroblastoma cells and recombinant 5-HT 3 receptors expressed in oocytes. 4, 5, 13 Intravenous anesthetics, such as thiopental, etomidate, alfaxalone, and propofol, inhibited 5-HT 3 receptor-mediated currents in N1E-115 cells, 7, 21 whereas propofol has been shown to have no significant effect at clinical concentrations in recombinant 5-HT 3A receptors. 5 Jenkins et al. 4 reported diverse effects of n-alcohols on the 5-HT 3 receptor; the lower alcohols, such as butanol and hexanol, potentiated the 5-HT 3 receptor at low concentrations but inhibited it at high concentrations, and the higher alcohols, such as octanol and decanol, inhibited the 5-HT 3 receptor at any concentration. Little is known about the effects of gaseous anesthetics, such as N 2 O and Xe, on the 5-HT 3 receptor. Recently, Yamakura et al. 12 reported that a recombinant 5-HT 3 receptor was slightly inhibited by N 2 O. N 2 O and Xe had a similar type of effect on other ligand-gated ion channels, although there are no data available about the interaction between Xe and the 5-HT 3 receptor. According to the results of this study, isoflurane and halothane had a potentiating effect on the 5-HT 3 receptor, whereas sevoflurane, N 2 O, and Xe produced inhibitory effects. Like other ligand-gated ion channels, the 5-HT 3 receptor can be directly modulated by general anesthetics, but it produces diverse effects. Interestingly, this is in contrast to the effect on the GABA A receptor, which is potentiated by most anesthetics. 2 It is interesting to note that the inhibitory effects of N 2 O and Xe on the 5-HT 3 receptor are competitive with no voltage dependency, whereas that of sevoflurane is noncompetitive. The evidence that both thiopental 4 and alfaxalone 21 inhibit the 5-HT 3 receptor in a noncompetitive manner suggests that sevoflurane may share a similar inhibitory mechanism of action with these anesthetics. Yamakura et al. 12 investigated the effects of N 2 O and Xe on several kinds of ligand-gated ion channels, and the inhibition of NMDA and nACh receptors by N 2 O was noncompetitive with the voltage dependencies. It has been reported that the inhibitory mechanism of Xe was also noncompetitive for the NMDA receptor. 22 The mechanisms of action of N 2 O and Xe at the 5-HT 3 receptor might be different from those at the NMDA and nACh receptors. The molecular determinant of the sensitivities to N 2 O and Xe has been identified in the nACh receptor 23 as a single amino acid near the middle of the second transmembrane segment of the ␤ 2 or ␤ 4 subunit of the nACh receptor. There are no data available for the molecular site of action of N 2 O and Xe in the NMDA receptor. According to our results on the 5-HT 3 receptor, N 2 O and Xe might act at the agonist recognition site for 5-HT rather than at the channel pore in the 5-HT 3 receptor. It is also possible that there might be multiple modulatory sites for these anesthetics in the agonist recognition domain of the 5-HT 3 receptor. 4, 5 Specific amino acid residues that seem to form part of the 5-HT binding site in the recombinant 5-HT 3 receptor have been identified as a glutamate residue 24 at 106 and tryptophan residues at 90, 183, and 195 in the N-terminal loops. 25 Further mutagenesis studies on these residues of the 5-HT 3 receptor will be required to reveal the detailed site of action for N 2 O and Xe.
Recently, much interest has focused on the role of the 5-HT 3 receptor in PONV because specific 5-HT 3 receptor antagonists have been reported to clinically decrease the incidence of PONV. 9 -11 These results suggest that anesthetics that inhibit the 5-HT 3 receptor might cause less PONV than those that substantially potentiate 5-HT 3 receptor function. In the current study, we showed that halothane and isoflurane potentiated the 5-HT 3 receptor but, surprisingly, that sevoflurane, N 2 O, and Xe inhibited the 5-HT 3 receptor. According to clinical research about PONV after sevoflurane and isoflurane anesthesia, the incidence of PONV was lower in the sevoflurane group than in the isoflurane group. 26 Potentiation by halothane was much greater than that of isoflurane, consistent with a clinical study that showed the incidence of PONV after halothane anesthesia also to be greater than that of sevoflurane. 27 However, N 2 O, which is thought to cause clinical emesis, 28 and Xe did not potentiate the 5-HT 3 receptor but rather inhibited it at clinical concentrations. Although little is known about the effects of Xe in terms of PONV, a study examining the analgesic potency of Xe reported nausea in 30% of volunteers. 29 Therefore, it is unlikely that all the effects of anesthetics on the 5-HT 3 receptor have an important role in producing PONV, although the potentiation of the 5-HT 3 receptor by halothane and isoflurane might be partly involved in the mechanism associated with their anesthesia. No clear conclusion is possible as to whether the effects of anesthetics on the 5-HT 3 receptor can be related to the clinical cause for PONV.
In this study, we showed volatile and gaseous anesthetics had diverse actions on the 5-HT 3 receptor. Both halothane and isoflurane were confirmed as enhancing homomeric 5-HT 3 receptor function in a concentrationdependent manner. In contrast, we revealed that sevoflurane inhibited the 5-HT 3 receptor noncompetitively, and N 2 O and Xe inhibited the 5-HT 3 receptor competitively.
